Code | CSB-EL012895HU |
Size | 96T,5×96T,10×96T |
Price | Request a Quote or Start an on-line Chat |
Trial Size |
24T ELISA Kit Trial Size (Only USD$150/ kit) * The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now |
Intra-assay Precision (Precision within an assay): CV%<8% | ||||||
Three samples of known concentration were tested twenty times on one plate to assess. | ||||||
Inter-assay Precision (Precision between assays): CV%<10% | ||||||
Three samples of known concentration were tested in twenty assays to assess. | ||||||
To assess the linearity of the assay, samples were spiked with high concentrations of human LGALS9 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. | ||||||
Sample | Serum(n=4) | |||||
1:1 | Average % | 92 | ||||
Range % | 86-97 | |||||
1:2 | Average % | 100 | ||||
Range % | 95-104 | |||||
1:4 | Average % | 88 | ||||
Range % | 83-94 | |||||
1:8 | Average % | 94 | ||||
Range % | 87-99 |
The recovery of human LGALS9 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. | ||||||
Sample Type | Average % Recovery | Range | ||||
Serum (n=5) | 88 | 83-93 | ||||
EDTA plasma (n=4) | 96 | 92-101 | ||||
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
This human LGALS9 ELISA kit employs the quantitative sandwich enzyme immunoassay technique to measure the levels of human LGALS9 in different samples, including serum, plasma, cell culture supernates, or tissue homogenates. The enzyme-substrate chromogenic reaction is also used to amplify the signal and quantify the levels of the analyte through the intensity of the colored product. The color intensity positively correlates with the amount of LGALS9 bound in the initial step.
LGALS9 is secreted out upon cell damage and acts as an apoptosis-inducing factor that binds to TIM-3 on Th1 cells. It elicits a set of events such as calcium mobilization, calpain and caspase-1 activation that drives the Th1 cells to apoptosis. It has been involved in multiple biological processes, including glycoprotein trafficking, cell-cell or cell-extracellular matrix interaction, signal transduction, immune response, development, and oncogenesis. LGALS9 modulates the threshold of B cell activation. Engagement of LGALS9 alters the organization of the B cell receptor (BCR), boosting interactions with inhibitory co-receptors CD45 and CD22, thereby reducing BCR signal transduction.
There are currently no reviews for this product.